Contents

• Clinical Review
  • Executive Summary
  • Introduction
  • Perspectives of Patients, Clinicians, and Drug Programs
  • Clinical Evidence
  • Discussion
  • Conclusion
  • Abbreviations
  • Appendix 1. Detailed Outcome Data
  • References
• Pharmacoeconomic Review
  • Executive Summary
  • Input Relevant to the Economic Review
  • Economic Review
  • Abbreviations
  • Appendix 1. Cost Comparison Table
  • Appendix 2. Submission Quality
  • Appendix 3. Additional Information on the Submitted Economic Evaluation
  • Appendix 4. Additional Details on the CDA-AMC Reanalyses and Sensitivity Analyses of the Economic Evaluation
  • Appendix 5. Submitted Budget Impact Analysis and CDA-AMC Appraisal
  • References

Canada’s Drug Agency (CDA-AMC) is a pan-Canadian health organization. Created and funded by Canada’s federal, provincial, and territorial governments, we’re responsible for driving better coordination, alignment, and public value within Canada’s drug and health technology landscape. We provide Canada’s health system leaders with independent evidence and advice so they can make informed drug, health technology, and health system decisions, and we collaborate with national and international partners to enhance our collective impact. 

Disclaimer: CDA-AMC has taken care to ensure that the information in this document was accurate, complete, and up to date when it was published, but does not make any guarantee to that effect. Your use of this information is subject to this disclaimer and the Terms of Use at cda-amc.ca.

The information in this document is made available for informational and educational purposes only and should not be used as a substitute for professional medical advice, the application of clinical judgment in respect of the care of a particular patient, or other professional judgments in any decision-making process. You assume full responsibility for the use of the information and rely on it at your own risk.

CDA-AMC does not endorse any information, drugs, therapies, treatments, products, processes, or services. The views and opinions of third parties published in this document do not necessarily reflect those of CDA-AMC. The copyright and other intellectual property rights in this document are owned by the Canadian Agency for Drugs and Technologies in Health (operating as CDA-AMC) and its licensors.

Questions or requests for information about this report can be directed to [email protected].

Sponsor: Janssen Inc.

Therapeutic area: Locally advanced or metastatic non-small cell lung cancer